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The ideal cancer treatment should both destroy the primary tumour and at the same time educate the immune system to recognise
the tumour as foreign so that distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the i.v. administration
of photosensitisers followed by illumination of the tumour with red light producing reactive oxygen species that eventually cause
vascular shutdown and tumour cell death by apoptosis and necrosis. Anti-tumour immunity is stimulated after PDT due to the acute
inflammatory response, generation of tumour-specific antigens, and induction of heat-shock proteins. Green fluorescent protein
(GFP) is used as an optical reporter to noninvasively image the progression of mouse tumours, and in addition, may act as a foreign
(jellyfish) antigen. We asked whether GFP-expressing tumours could be used to monitor the response of tumour-bearing mice to
PDT, and whether the tumour response differed when a nonimmunogenic tumour cell line was transduced with GFP. We injected
RIF-1 or RIF-1 EGFP (stably transduced with a retroviral vector) cells in the leg of C3H/HeN mice and both the cells and tumour
grew equally well. We used PDT with benzoporphyrin derivative and a short drug-light interval. There were complete cures and
100% mouse survival of RIF-1 EGFP while RIF-1 wild-type tumours all recurred. Cured mice were resistant to rechallenge with RIF-1
EGFP cells and a rechallenge with wild-type RIF-1 cells grew significantly slower. There was also slower RIF-1 EGFP rechallenge
growth but no rejection when RIF-1 EGFP tumours were surgically removed. There was a low rate of PDT cure of tumours when
RIF-1 cells were transduced with an empty retroviral vector. The presence of antibodies against EGFP in mouse serum suggests EGFP
can act as a foreign antigen and PDT can then stimulate a long-term memory immune response.
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It was estimated that approximately 563700 Americans would die
of cancer in 2004 corresponding to over 1500 deaths per day
(Smith et al, 2004). Despite advances in early detection and
treatment, most patients still cannot be treated effectively and
eventually die, largely due to metastatic disease. The ideal cancer
treatment should destroy both the primary tumour and at the same
time educate the immune system to recognise the tumour as
foreign so that, after the primary tumour is destroyed, distant
metastases will also be eradicated.
Photodynamic therapy (PDT) uses a nontoxic photoactivatable
dye or photosensitiser (PS) in combination with harmless visible
light that produces reactive oxygen species and destroys tumour
tissue (Dolmans et al, 2003). Photodynamic therapy is approved for
multiple indications in the United States, and many other countries
(Dougherty, 2002). Mechanisms that have been shown to be involved
in the tumouricidal effect include direct cytotoxicity to tumour cells,
shutting down of the tumour vasculature starving the tumour of
oxygen or nutrients, and the induction of a host immune response
(Dougherty et al, 1998). The precise mechanisms involved in the
PDT-mediated induction of antitumour immunity are not yet
completely understood (Korbelik, 1996). Among the potential
contributing factors are alterations in the tumour microenvironment
via stimulation of proinflammatory cytokines and direct effects of
PDT on the tumour that increase immunogenicity (Canti et al, 2002).
In contrast to common cancer therapies such as surgery, radiation
therapy and chemotherapy that are all more or less immunosup-
pressive, PDT can stimulate the immune response to cancer.
Green fluorescent protein (GFP) was originally isolated from the
jellyfish, Aequorea victoria (Chalfie, 1995). Enhanced GFP (EGFP)
is a red shifted variant, which fluoresces much more intensely than
wild-type GFP (Sacchetti et al, 2000). Hoffman and coworkers
(Hoffman, 1999a,b, 2001, 2002a) have introduced the concept of
in vivo monitoring of GFP expressing tumours using macroscale
fluorescence imaging, There are some reports that GFP can be
immunogenic when expressed in mouse tumours (Stripecke et al,
1999; Gambotto et al, 2000; Brown et al, 2001). In this report, we
asked whether GFP-expressing tumours could be used to monitor
the response of tumour-bearing mice to PDT, and whether the
tumour response differed when a nonimmunogenic tumour cell
line was transduced with GFP.
MATERIALS AND METHODS
Cell line and tissue culture conditions
The radiation-induced fibrosarcoma (RIF-1) tumour cells origin-
ally characterised by Twentyman et al (1980), were grown in RPMI
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s1640 media containing HEPES, glutamine, 10% fetal calf serum,
100Uml
 1 penicillin and 100mgml
 1 streptomycin. They were
collected for injection by washing with PBS without Ca
2þ and
Mg
2þ, and adding trypsin-EDTA to the plate for 10min at 371C.
Stable expression of EGFP
The retroviral plasmid vector (pLEGFP-N1, cat# 6059-1) expres-
sing the enhanced GFP (EGFP) was purchased from BD Clontech
(Palo Alto, CA, USA), and propagated in Escherichia coli DH5a
(Sigma, St Louis, MO, USA). The plasmid was then purified with
the Plasmid Kit from Qiagen (Valencia, CA, USA) as instructed. A
packaging cell line (AmphoPack-293, BD Clontech) was trans-
fected with the plasmid vector using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA, USA) as described for the reagent. Medium
containing the retrovirus was collected after 48h post-transfection,
filtered through a 0.45mm membrane, and used to infect the RIF-1
cells, as described in the retroviral gene expression user manual.
Radiation-induced fibrosarcoma cells permanently expressing
EGFP (RIF-1 EGFP) were initially cultured in 2mgml
 1 G418
and selected for EGFP expression by limiting dilution and
fluorescence microscopy. This was carried out in order to pick a
stable and bright level of fluorescence. Cells were not routinely
maintained with G418 but were used for a maximum of six
passages and EGFP expression levels were checked at passage 6 by
FACS analysis. Additional RIF-1 cells were transduced with the
empty retroviral vector (pLNCX2, cat# 6102-1) lacking the gene for
EGFP and selected and routinely cultured in the presence of
2mgml
 1 G418. These were termed RIF-1 EPV.
Mice and tumour model
All animal experiments were approved by the Subcommittee on
Research Animal Care of Massachusetts General Hospital and were
in compliance with NIH guidelines. Male C3H/HeN mice (Charles
River Labs, Boston, MA, USA), weighing 20–25g were shaved on
the right thigh and depilated with Nair (Carter-Wallace Inc New
York, NY, USA). Mice were anaesthetised with an i.p. injection
of ketamine/xylazine cocktail (90mgkg
 1 ketamine, 10mgkg
 1
xylazine). One million RIF-1 cells or RIF-1 EGFP cells were
injected subcutaneously in one mid-thigh area suspended in 100ml
PBS. Tumours grew predictably in all mice and reached a size of
5–6-mm diameter 8–9 days after injection at which time they were
used for PDT. Some mice had their tumours removed by surgical
amputation of the tumour bearing leg at the same time point
(5–6mm diameter).
Anti-EGFP serum antibodies
An ELISA assay for mouse anti-EGFP detection was modified from
that of Brown et al (2001). Briefly, recombinant EGFP (BD
Clontech) was diluted into 10mM Tris pH 8.5 at 2mgml
 1, and
50ml was added into each well of 96-well MaxiSorp ELISA plate
(Nunc, Rochester, NY, USA), incubated at room temperature for
90min. The wells were then blocked by incubating with PBS
containing 1% BSA for 1h at room temperature, and washed three
times with PBS containing 0.05% Tween 20 (PBS-T). Mouse serum
(10ml) was diluted into 100ml PBS-T and added to the wells,
incubated for 2h at room temperature. Then the serum was
removed and the wells washed three times with the PBS-T.
Captured mouse anti-EGFP was detected with an alkaline
phosphatase-conjugated secondary antibody (Biostain, Foster City,
CA, USA) and D-nitrophenylphosphate (Sigma). Optical absor-
bance at 405nm was read at 60min on a plate reader (Molecular
Dynamics). A calibration curve was constructed using known
amounts of mouse IgG coated on wells of a plate and the same
alkaline phosphatase-conjugated secondary antibody, that allowed
the OD at 405nm to be converted tomgml
 1 IgG.
In vivo fluorescence imaging
Mice bearing GFP expressing tumours were lightly anaesthetised
with an i.p. injection of ketamine/xylazine cocktail (45mgkg
 1
ketamine, 5mgkg
 1 xylazine) and were imaged in a macrofluor-
escence imaging system (Lightools Research, Encinatas, CA, USA).
Incandescent white light (Illumatools, Lightsource Research) was
filtered through a 450–490 band pass filter and a liquid light guide
to provide illumination from two parallel angled light diffusers
positioned 25cm above the mouse. Emission light passed through
a 500-nm long pass filter into an Optronics CE (Goleta, CA, USA)
colour charge-coupled device camera via a f1.4 zoom lens. The
camera was controlled by Magnafire SP software (Optronics) and
an acquisition time of 2.468s and a white balance of 2800K were
used to capture images of 1280 by 1024 pixels. Adobe Photoshop
(San Jose, CA, USA) was used to compile time course composite
images.
On day 20 after tumour injection tumour-bearing animals were
killed with carbon dioxide, and dissected with a midline skin
incision extending from the caudal abdomen to the lower jaw, the
skin was reflected and an incision into the abdominal cavity just
cranial to the external genitalia permitted visualisation of the
viscera. The incision was extended to the rib cage by cutting
abdominal musculature on both sides and reflected over the thorax
to expose the abdominal contents; the liver was reflected cranially
to expose the stomach. The spleen and the lymph nodes in the
retroperitoneum were seen. All the necropsy procedures were
followed with GFP imaging to detect any metastasis.
Photodynamic therapy
BPD (liposomal benzoporphyrin derivative mono-acid ring A,
Verteporfin for Injection) was a generous gift from QLT Inc.
(Vancouver, BC, Canada) as a lyophilised powder, which was
reconstituted with 5% dextrose solution and injected at a dose of
2mgkg
 1 in 0.1ml solution via the lateral tail vein. Photodynamic
therapy was carried out at 15min after injection for BPD using
an 1W solid state diode laser (High Power Devices Inc., North
Brunswick, NJ, USA) emitting light at 690nm (72nm). The laser
was coupled into a 400-mm fibre via a SMA connector and light
from the distal end of the fibre was focused into a uniform spot
with an objective lens (No 774317, Olympus, Tokyo, Japan). The
spot had a diameter of 1.2cm and was positioned so that the entire
tumour and a surrounding 2–3mm of normal tissue was exposed
to light. Mice were anaesthetised as described above and the
tumour bearing leg positioned under the spot. A total fluence of
150Jcm
 2 was delivered at a fluence rate of 100mWcm
 2. Some
mice had their RIF-1 or RIF-1 EGFP tumours illuminated without
having received a prior injection of BPD. At the completion of the
illumination mice were allowed to recover in an animal warmer
until they resumed their normal activity.
Follow-up of mice and tumour rechallenge
Mice were examined three times a week. They were weighed and
the orthogonal tumour dimensions (a and b) were measured with
vernier calipers. The tumour volume was calculated according to
the formula, volume¼4/3 p{(aþb)/4}
3. Tumours were treated
when 5–6mm in diameter (volume E70–110mm
3). Mice were
imaged in the GFP camera if their tumour was EGFP expressing.
Mice were killed according to the protocol when the tumours
reached a largest diameter of 1cm. Mice were considered
cured when the tumour did not return after 60 days. Cured mice
or surgically amputated mice were rechallenged with one
million tumour cells (RIF-1 EGFP or RIF-1) injected in the
opposite leg to the one that had previously borne the primary
tumour.
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All values are expressed as7s.e. of the mean. Comparison between
two means was carried out using the Mann–Whitney U-test.
Survival analysis was performed using the Kaplan–Meier method.
Survival curves were compared, and differences in survival were
tested for significance using a log-rank test in the computer
program GraphPad Prism (GraphPad Software Inc., San Diego, CA,
USA). The tumour growth curves were analysed by transforming
the data to a logarithmic scale and comparing the slopes. P-values
of o0.05 were considered significant.
RESULTS
Growth rate of RIF-1 EGFP cells and tumours
It was necessary to ensure that the stable expression of the EGFP
gene via a retrovirus, did not have any deleterious effects on either
the growth rate of the tumour cells in tissue culture, or the growth
rate of the tumours when subcutaneously implanted into C3H
mice. The doubling times of the RIF-1, RIF-1 EGFP and RIF-1 EPV
cells in tissue culture were not statistically different (data not
shown). As can be seen from Figure 1 there were no significant
differences in the growth of the three tumours.
Fluorescence imaging of growth of RIF-1 EGFP tumour
Fluorescence imaging was used to noninvasively visualise the
progression of the EGFP-expressing tumours. In Figure 2 we show
the progression of an untreated RIF-1 EGFP tumour that was
permitted to grow until the 17th day (tumour diameter 12mm).
The mouse was killed and the necropsy procedure carried out as
described. Using the macrofluorescence imaging system, we found
two liver metastases with sizes between 2 and 3mm, without any
other organ compromised, and we did not find any lymph node
metastasis.
Anti-EGFP serum antibodies
Blood (100ml) was withdrawn via the orbital plexus from mice
bearing RIF-1 or RIF-1 EGFP tumours, allowed to clot and serum
obtained. Serum samples were analysed for the presence of anti-
EGFP antibodies as described in Materials and Methods. Figure 3
shows that mice with RIF-1 EGFP but not RIF-1 tumours
developed antibodies to EGFP by the 12th day after tumour
injection. We also asked whether PDT of RIF-1 EGFP tumour
bearing mice led to a drop in their titre of anti-EGFP antibodies
and as can be seen there was no difference between the control and
PDT-treated mice.
PDT response
Wild-type RIF-1 tumours were treated with PDT at days 8–9
(when tumours had a diameter of 5–6mm). We used BPD
(2mgkg
 1 i.v. followed after 15min by 150Jcm
 2 delivered at
100mWcm
 2). At 1 to 2 days after PDT the mice exhibited a black
eschar confined to the area formerly occupied by the tumour, It
was difficult to determine how much tumour was left under the
black eschar but in all mice the volume of the tissue measured
decreased after PDT. However, in all mice the tumours regrew,
frequently forming a ring of viable rapidly growing tumour outside
the black eschar. When RIF-1 EGFP tumours were treated under
the same conditions with BPD-PDT we observed interesting and
surprising differences in the responses. Firstly the tumour
shrinkage was more marked with RIF-1 EGFP tumours than was
found with RIF-1 tumours. Secondly, the subsequent behavior of
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Figure 1 Growth rate of RIF-1, RIF-1 EGFP and RIF-1 EPV tumours
injected subcutaneously in C3H/HeN mice.
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DAY 17 DAY 13
DAY 7 DAY 10
MET 2 MET 1
Figure 2 Series of in vivo fluorescence images of a RIF-1 EGFP tumour growing in the leg of a C3H mouse. The images labeled MET 1 and 2 were
captured at autopsy and show metastases in the liver.
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sthe tumours was very different. The RIF-1 EGFP tumours
disappeared completely by day 20 and did not return during the
40 days they were followed. The progress of one mouse bearing
a RIF-1 EGFP tumour treated with BPD-PDT and monitored
with fluorescence imaging is depicted in Figure 4. The reduction
in EGFP fluorescence is clearly visible 1 day after PDT, and
subsequent imaging at later time points revealed no remaining
fluorescence. The differences in mean tumour size between the
wild-type and EGFP-transduced tumours when treated with BPD-
PDT is shown in Figure 5. There was no difference in growth rate
between RIF-1 tumours or RIF-1 EGFP tumours exposed to red
light without BPD and the growth rate of untreated RIF-1 or RIF-1
EGFP tumours (data not shown).
In order to check whether the retrovirus used to produce stable
expression of EGFP was involved in this altered response to PDT,
we produced RIF-1 cells that had been infected with a retrovirus
produced from an empty plasmid vector (RIF-1 EPV). There was
no difference between in vivo tumour growth rates observed in
mice bearing these RIF-1 EPV tumours and either of the other RIF-
1 variants tested previously (Figure 1). When mice bearing RIF-1
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Figure 3 Detection of anti-EGFP antibodies. Recombinant EGFP was
coated to the surface of 96-well ELISA plate, and serum was added and
incubated as described in Materials and Methods. Anti-EGFP antibody in
serum captured was detected with alkaline phosphatase conjugated-
secondary antibody and chromogenic substrate D-nitrophenylphosphate.
OD405 was read at 60min. Data represent the averages of triplicates and
two independent experiments. Significantly different from wild-typeRIF-1:
**Po0.01; ***Po0.001 by Mann–Whitney U-test.
DAY 1 DAY 3 DAY 7
DAY 10 DAY 17 DAY 20
Figure 4 Series of in vivo fluorescence images of a RIF-1 EGFP tumour growing in the leg of a C3H mouse. The mouse was treated with BPD-mediated
PDT on day 9.
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Figure 5 Tumour response of wild-type RIF-1, RIF-1 EGFP and RIF-1
EPV tumours that had been treated with BPD-mediated PDT as described.
Tumour volume was calculated from dimensions measured with vernier
calipers twice a week. There were 10 mice in RIF-1, 13 mice in RIF-1 EGFP
and 12 mice in RIF-1 EPV groups, and bars are s.e.m. Significant differences
between RIF1 and RIF1 EGFP; *Po0.05 and **Po0.001 by Mann–
Whitney U-test.
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sEPV tumours were treated with BPD-PDT there were two out of 12
mice that had long-lasting responses, that is, no local recurrence
of tumour in 60 days. The remaining 10 out of 12 demonstrated
local recurrence but these recurrent tumours grew slower than the
recurrent wild-type RIF-1 tumours as shown in Figure 5, although
the error bars are large due to combining cured and tumour
progressing animals. The Kaplan–Meier survival curves (time to
kill due to tumour dimensions exceeding 1cm) for the three
groups of tumours are presented in Figure 6.
Mice that were cured of RIF-1 EGFP tumours by BPD-PDT, mice
that had their RIF-1 EGFP tumours surgically removed and
untreated control mice were rechallenged by a second injection of
1 million RIF-1 EGFP cells after they had been tumour-free for 60
days. All the mice that had been cured of RIF-1 EGFP tumours by
BPD-PDT rejected the subsequent tumour rechallenge (0 out of
eight grew tumours), while all of the surgically cured mice (five out
of five), and all of the naı ¨ve mice that were challenged with RIF-1
EGFP cells grew tumours (five out of five). However, the growth
rate of the surgically cured mice rechallenged with RIF-1 EGFP
was significantly slower than the growth rate of naive RIF-1 EGFP
tumours (Po0.001 by comparing slopes of logarithmic trans-
formed data). Five mice that had been cured of RIF-1 EGFP
tumours and rejected a subsequent rechallenge with RIF-1 EGFP
tumour cells were rechallenged with one million wild-type RIF-1
cells together with naı ¨ve mice. The RIF-1 tumours grew in all the
mice but again the rate of growth of RIF-1 cells in mice cured
of RIF-1 EGFP tumours by PDT was significantly slower than the
rate in naı ¨ve mice (Po0.001 by comparing slopes of logarithmic
transformed data) than in naı ¨ve mice (Figure 7). There were no
long-term survivors in this group of mice.
DISCUSSION
In this study, we have shown that there are significant and
unexpected differences in the response to PDT of mouse tumours
that are either wild-type or stably expressing EGFP. The repetitive
imaging of mice with GFP-expressing tumours using a macro-
fluorescence imaging system is very useful tool to follow tumour
progression and to test new therapeutic approaches (Kamiyama
et al, 2002; Wang et al, 2003). However, many of these reports on
GFP-tumour imaging used human tumour cell lines expressing
GFP and therefore were constrained to employ immunosuppressed
nude or SCID mice (Yamamoto et al, 2003). This fact may have led
to a delay in the realisation that the jellyfish protein GFP can act as
a foreign model tumour antigen in immunocompetent mice.
Similar sea-borne materials and their derivatives, such as glycated
chitosan, have also been used in experiments designed to induce
antitumour immunity with laser–dye interactions (Chen et al,
1999). Mice are the ideal model in which to employ GFP-tumours
because they are small animals suitable for placement in cameras
with restricted space and the tumours generally are relatively near
the surface due to the small total body volume of a mouse
(Hoffman, 2002b). We found liver metastases easily by GFP
imaging, while traditional examination of organs by histopatho-
logy is tedious and labour intensive. Twentyman reported
(Twentyman et al, 1980) an ‘occasional lung metastasis’ from
wild-type RIF-1 tumours but did not find liver metastases.
However, when GFP-expressing mouse tumours are used in
syngeneic immunocompetent mice it is important to consider
the potential immunogenicity of GFP. Our findings that PDT
mediated by BPD produces a 100% cure rate of RIF-1 tumours that
stably express EGFP while having only a small temporary effect
against wild-type RIF-1 tumours, suggests that the presence of the
‘foreign’ protein EGFP is recognised by the mouse immune system.
However, the observation that RIF-1 EGFP tumours have the same
growth rate in C3H mice as wild-type RIF-1 tumours suggests that
another immunopotentiating stimulus is necessary to engender
the full immune response against the tumour. In our case, this
second immune activating stimulus is BPD-mediated PDT.
Similar induction of anti-tumour immunity has been reported
using a selective photothermal interaction in combination with an
intratumour administration of immunoadjuvant (Chen et al,
2002). The result of the EGFP expression seems to have been to
increase the immunogenicity of the tumour in a controlled
manner; that is enough for PDT to produce a curative effect, but
not enough to affect growth in control mice. The fact that
RIF-1 EGFP can be metastatic emphasises the necessity of the
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Figure 6 Kaplan–Meier curve. Mice bearing RIF-1, RIF-1 EGFP and RIF-1
EPV tumours were treated with BPD-PDT as described. Mice were killed
when tumours reached a diameter of 1cm. *All three curves were
significantly different (Po0.01) by log-rank analysis.
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Figure 7 Tumour growth curves of naı ¨ve mice or cured mice
rechallenged with tumour cells. Mice that had been cured of RIF-1 EGFP
tumours by PDT or surgery were rechallenged with RIF-1 EGFP or wild-
typeRIF-1. Tumour volume was calculated from dimensions measured with
vernier calipers twice a week. There were five mice in each group. ***The
curves showed significant differences compared to naı ¨ve mice (Po0.001) in
tumour growth rate by logarithmic transformation and slope comparison.
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sinvolvement of the host immune system in producing lasting cures
by PDT. Even if the local tumour were completely destroyed by
PDT, mice may still die of distant metastases.
There have been several reports on the generation of anti-
tumour immunity in mouse or rat cancer models by PDT
(Korbelik and Cecic, 1999; Korbelik and Dougherty, 1999) and
also by a related photothermal technology (Chen et al, 2003). It is
thought that tumour-specific cytotoxic T lymphocytes can be
generated by these therapies and that these account for the long-
term memory immune response against the tumour (Korbelik
et al, 2001). One advantage of using EGFP-expressing tumours to
demonstrate PDT-induced antitumour immunity is that it appears
that EGFP represents a defined model tumour antigen that can
mediate the immune response against the tumour.
The potential immunogenicity of GFP in mice was first reported
by Stripecke et al (1999) who found that stable expression of EGFP
in two mouse tumours inhibited tumour growth and led to
formation of cytotoxic CD8 T cells that recognise EGFP-expressing
cells. The identification of EGFP 200–208 as an H-2Kd-restricted
cytotoxic-T-lymphocyte (CTL) epitope by Gambotto et al (2000)
further defined EGFP as a model tumour antigen. Other workers
have found that implantation of EGFP-expressing tumours in mice
has induced the presence of anti-EGFP IgG antibodies in the serum
(Brown et al, 2001; Spiotto et al, 2003).
Cellular and humoral immune response against GFP have been
observed in rhesus macaques that underwent haematopoietic stem
cell transplantation with EGFP-transduced CD34þ cells; in this
study they found that the EGFP-specific CTL responses were MHC-
restricted, mediated by CD8þ lymphocytes, and directed against
multiple epitopes (Rosenzweig et al, 2001). Another study showed
that GFP, delivered into dendritic cells (DCs) by an adenoviral
vector or following protein pulsing, could significantly modify
DC phenotype, into a terminal maturation-like process which
enhanced their immunostimulatory capacity (Re et al, 2004).
Other foreign antigens have been genetically engineered to be
expressed in tumour cells and have been used to increase the
humoral and/or cellular immunity against cancer in mice.
Ovalbumin (a chicken protein) is processed and presented through
MHC I with generation of tumour-specific CTL. This system has
been used to test several approaches involving cancer vaccination
strategies (Nelson et al, 2001; Chung et al, 2004; van Broekhoven
et al, 2004).
It has been shown that tumour cells expressing beta-galactosi-
dase (a bacterial protein) also can induce a strong cellular immune
response against the antigen (Wang et al, 1995b). (Wang et al
(1995a) reported that CT26 mouse colon cancer cells expressing
beta-galactosidase, formed tumours that could be treated with
virus-mediated immunotherapy while the wild-type tumours were
resistant.
The fact that we observed a small number of cures (17%) when
tumours formed from RIF-1 cells that had been transduced with
the empty retroviral vector as a control (RIF-1 EPV, Figure 6) were
treated with PDT, and the tumours that recurred (83%) grew
significantly slower than recurrent wild-type RIF-1 tumours, shows
that not only EGFP can act as a foreign antigen in the present
system. Presumably some of the genes in the retrovirus encode
proteins that can also act as model tumour antigens, although to a
much lesser extent than EGFP.
The generation of a long-term memory immune response as
demonstrated by the resistance of cured mice to rechallenge with
RIF-1 EGFP cells was not unexpected. Reports have demonstrated
that the production of anti-tumour immunity by curing tumours in
mice either by PDT (Canti et al, 1994) or by other methods (Suzuki
et al, 2003), and have shown a resistance to rechallenge by the same
tumour cells that formed the primary tumour. The baseline level of
immunogenicity of the EGFP expressing tumours is confirmed by
the data that a rechallenge of mice whose RIF-1 EGFP tumours had
been surgically removed with the same RIF-1 EGFP cells led to a
significantly reduced rate of tumour growth but no outright
rejection. However, the finding that wild-type RIF-1 tumours grew
significantly slower in mice cured from RIF-1 EGFP tumours than
in naı ¨ve mice was surprising. The RIF-1 cell line has always been
considered to be poorly immunogenic, but our data implies that it
does contain partly effective tumour antigens that can be
recognised by the immune system when subjected to stimulation
by the PDT-induced creation of anti-tumour immunity.
There is a considerable amount of work remaining to be done to
understand these results. Our future work will be focused on the
identification of the immune mechanisms behind the immunity
generated by PDT against GFP and wild-type tumours. We need to
do additional work to establish the role that EGFP is playing in
comparison with the retroviral vector used to transduce the cells.
However, the presence of anti-GFP antibodies before PDT suggests
that the effect is primarily mediated by the foreign jellyfish
antigen. We will investigate whether mice cured of RIF-1 EGFP
tumours also have immunity against other EGFP-expressing
tumours cells syngeneic to C3H mice.
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